BeNeLuxBelgiumNetherlandsLuxembourg

Qiagen to acquire stake in Alacris

12.01.2011

Hilden/Berlin – Qiagen NV has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a pioneer in the field of deep sequencing based therapy guidance, clinical trial stratification, and biomarker identification. With its minority stake, Qiagen acquires an exclusive option to access all biomarkers dicovered with Alacris’ ModCell™ system. Alacris will participate in commercialization of these biomarkers through royalty fees. Financial details of the agreement were not disclosed. ModCell™, which was invented by Alacris co-founder Prof. Hans Lehrach from Max Planck Institute for Molecular Genetics (MPI-MG) in Berlin uses a proprietary modelling system and can be used to identify the right therapy for a specific genotype (patient) and also to identify the right genotypes for a therapy (clinical trial stratification). The latter of the two applications leads to the identification of a companion diagnostic or biomarker set for that therapy. These marker selections can be formatted into real-time PCR-based assays that QIAGEN can then commercialize within its pharmaceutical development assay portfolio or its therascreen molecular diagnostics portfolio for use on its new QIAsymphony RGQ platform. “Our strategic investment in Alacris expands QIAGEN’s existing broad biomarker discovery and validation initiatives and is designed to expand our QIAsymphony-based personalized healthcare and pharma development assay portfolio,” said Peer Schatz, Chief Executive Officer of QIAGEN. “With QIAGEN, we have not only engaged a financially strong investor but also a leader in personalized healthcare as our partner,” said Prof. Dr. Hans Lehrach. Biomarkers play an increasingly important role in diagnostics and the development of new pharmaceutical agents. Experts estimate the overall market volume for biomarkers will be approximately $21 billion by 2012. The agreement will not affect marketing of Alacris’ sequencing-based therapy guidance to leading cancer clinics or clinical trial stratification business that is available to pharmaceutical companies in order to help them reduce the cost of bringing their oncology drugs to market and to increase the likelihood of a successful approval.

BeNeLuxBelgiumNetherlandsLuxembourg

16.12.2011

Mechelen - Galapagos NV confirms its status as one of Europe best drug discovery companies. The Belgian biotech received €4 million as the first milestone payments from French Servier for the discovery of new targets for...

BeNeLuxBelgiumNetherlandsLuxembourg

15.12.2011

Munich/Groningen/Penzberg – For ten years, the application of image-guided surgery with tumour-specific fluorescent dyes has been limited to animal studies, because no one could predict safety or bio­distribution of such targeted...

BeNeLuxBelgiumNetherlandsLuxembourg

02.12.2011

Zwijnaarde/Rotterdam – In vivo camelid antibody specialist arGEN-X BVBA has baged €27.5 million of fresh capital for development of its preclinical monoclonal antibody pipeline. The round B financing of the 3 year-old company,...

BeNeLuxBelgiumNetherlandsLuxembourg

28.11.2011

Brussels/Ghent – Belgian researchers have demonstrated that tumour cells secrete the angiogenesis factor VEGF to create a microenvironment that fosters proliferation of cancer stem cells. In mice with squamous cell carcinoma,...

BeNeLuxBelgiumNetherlandsLuxembourg

23.11.2011

Mechelen – Belgian drugmaker Galapagos NV has reported impressive results of a proof-of-concept trial with its oral janus kinase 1 blocker GLPG0634 + Methothrexate in patients with active rheumatoid arthritis. In the 24 patients...

BeNeLuxBelgiumNetherlandsLuxembourg

18.11.2011

Naarden – Enzyme replacement therapies specialist Oxyrane NV raised €20 million in a series D round of financing. The therapies are designed to treat lysosomal storage diseases, a class of more than forty rare inherited diseases....

BeNeLuxBelgiumNetherlandsLuxembourg

14.11.2011

Hilden/Venlo – Sample and assay technologies provider Qiagen N.V. is set to eliminate about 10% of its current global workforce of 3,800 employees. The company says the cuts are one result of implementing a project aimed at...

BeNeLuxBelgiumNetherlandsLuxembourg

09.11.2011

New York/Ghent - Big brother is gone. Belgian biotech Ablynx regained the rights for nanobodies targeting TNF-alpha from Pfizer. The US- pharma outfit decided it did't want ATN-103, even though it met its goal in a mid-stage...

BeNeLuxBelgiumNetherlandsLuxembourg

25.10.2011

Amsterdam - The second blow could be the ultimate one. Amsterdam Molecular Therapeutics received a second negative opinion for Glybera to treat lipoprotein lipase (LPL) deficiency. The European Medicines Agency's (EMA) Committee...

BeNeLuxBelgiumNetherlandsLuxembourg

13.10.2011

Bilthoven – The current impact of hospital acquired infections with multi-resistant bugs is lower than suggested by startling news articles. According to a study of Dutch researchers, bloodstream infections caused by...

Displaying results 11 to 20 out of 304

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/1/article/qiagen-to-acquire-stake-in-alacris.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MEDIGENE3.85 EUR8.15%
  • EVOTEC2.87 EUR7.49%
  • 4SC0.84 EUR5.00%

FLOP

  • CYTOS0.15 CHF-6.25%
  • EPIGENOMICS3.42 EUR-0.87%
  • STRATEC BIOMEDICAL37.50 EUR-0.87%

TOP

  • BIOFRONTERA2.91 EUR29.9%
  • ADDEX3.44 CHF5.8%
  • HBM86.00 CHF3.7%

FLOP

  • PAION2.19 EUR-32.6%
  • CYTOS0.15 CHF-28.6%
  • 4SC0.84 EUR-26.3%

TOP

  • SANTHERA82.00 CHF2269.9%
  • CO.DON2.82 EUR209.9%
  • PAION2.19 EUR154.7%

FLOP

  • CYTOS0.15 CHF-96.2%
  • 4SC0.84 EUR-51.7%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 21.10.2014


Current issue

All issues

Product of the week

Products